Carillon Tower Advisers, an funding administration firm, launched its “Carillon Eagle Progress & Revenue Fund” first quarter 2025 investor letter. A replica of the letter may be downloaded right here. The S&P 500 Index ended Q1 down 4.3%, marking a turbulent begin to 2025. The volatility that started in February was triggered by components together with coverage uncertainties, financial deceleration, and AI funding sustainability issues. The market’s first intra-quarter drawdown exceeded 10% in 28 months. Including to the uncertainty, the 10-year U.S. Treasury yield declined from 4.8% to 4.25%, resulting in an fairness market rotation favoring defensive sectors, high quality shares, and dividend-yielding equities over development and momentum-driven investments, with top-performing sectors like vitality, healthcare, and client staples. Furthermore, the quarter noticed market participation broaden, with index management shifting from mega-cap expertise corporations to a extra various base of shares, as evidenced by the S&P 500® Equal Weight Index’s outperformance. Moreover, you’ll be able to test the fund’s high 5 holdings to find out its finest picks for 2025.
In its first-quarter 2025 investor letter, Carillon Eagle Progress & Revenue Fund highlighted shares reminiscent of AbbVie Inc. (NYSE:ABBV). AbbVie Inc. (NYSE:ABBV) is a research-based biopharmaceutical firm. The one-month return of AbbVie Inc. (NYSE:ABBV) was 6.74%, and its shares gained 13.84% of their worth during the last 52 weeks. On Might 19, 2025, AbbVie Inc. (NYSE:ABBV) inventory closed at $185.71 per share with a market capitalization of $327.809 billion.
Carillon Eagle Progress & Revenue Fund acknowledged the next relating to AbbVie Inc. (NYSE:ABBV) in its Q1 2025 investor letter:
“AbbVie Inc. (NYSE:ABBV) issued higher than anticipated preliminary 2025 steerage and raised the long-term gross sales outlook for its two most vital medication. The inventory additionally benefited from the broader fairness market rotation into the healthcare sector, together with into extra defensive industries like biopharmaceuticals.”
A pharmacist handing out a pharmaceutical drug to a affected person in a drug retailer or chemist.
AbbVie Inc. (NYSE:ABBV) isn’t on our record of 30 Most Fashionable Shares Amongst Hedge Funds. As per our database, 85 hedge fund portfolios held AbbVie Inc. (NYSE:ABBV) on the finish of the fourth quarter, in comparison with 68 within the third quarter. Whereas we acknowledge the potential of AbbVie Inc. (NYSE:ABBV) as an funding, our conviction lies within the perception that AI shares maintain better promise for delivering greater returns, and doing so inside a shorter timeframe. If you’re on the lookout for an AI inventory that’s as promising as NVIDIA however that trades at lower than 5 occasions its earnings, take a look at our report in regards to the undervalued AI inventory set for large positive factors.